文献速递乳腺US

基于常规超声与CEUS的乳腺CEUS BI-RADS开发与验证

A New Contrast-Enhanced Ultrasound (CEUS) Reporting and Data System for Breast Lesions.
PubMed 文献 · Ultrasound Med Biol · 2026-09-25

这项回顾性多中心研究纳入1465例患者、1624个乳腺病灶,利用常规超声及CEUS定性特征通过多因素logistic回归开发CEUS BI-RADS。在内部验证集中,CEUS BI-RADS的AUC为0.95,显著高于常规US BI-RADS的0.80。CEUS BI-RADS同时降低了不必要活检率,展示了提高诊断效率的潜力。

要点

  • CEUS BI-RADS内部验证AUC为0.95,显著优于常规US BI-RADS的0.80。
  • CEUS BI-RADS不必要活检率从40%降至29%,可减少穿刺负担。
  • CEUS特征与常规超声联合可提高乳腺病灶恶性风险分层。

核心结论

  • 基于常规超声与CEUS特征开发的新CEUS BI-RADS在内部验证中诊断效能优于常规US BI-RADS。
  • CEUS BI-RADS在保持较高敏感度与特异度的同时显著降低了不必要活检率。

研究设计与样本

  • 回顾性多中心研究,纳入1465例患者的1624个乳腺病灶,来自三个中心。
  • 中心1患者按70%训练集与30%内部验证集随机划分,中心2和中心3构成外部验证集。
  • 所有病灶均接受常规超声、CEUS检查并获得最终诊断。

关键影像表现/征象

  • 研究分析了乳腺病灶的常规超声与CEUS定性特征。
  • 通过多因素logistic回归系数取整得到评分,构建CEUS BI-RADS。

诊断标准与关键数值

  • 内部验证集中,CEUS BI-RADS的AUC为0.95(95%CI:0.92,0.97),常规US BI-RADS为0.80(95%CI:0.76,0.85),p<0.001。
  • CEUS BI-RADS敏感度为90%(122/135),常规US BI-RADS为76%(103/135),p<0.05。
  • CEUS BI-RADS特异度为80%(205/255),常规US BI-RADS为73%(187/255),p<0.05。
  • CEUS BI-RADS阳性预测值为71%(122/172),阴性预测值为94%(205/218),均高于常规US BI-RADS(p<0.05)。
  • 不必要活检率由40%(68/171)下降至29%(50/172),p=0.037。

临床应用与阅片要点

  • CEUS BI-RADS结合常规超声与CEUS特征可提高乳腺病灶风险分层准确性。
  • 该分级系统在维持诊断效能的同时可减少不必要的乳腺穿刺活检。
  • 适用于需要更精准恶性风险分层以减少患者焦虑和医疗资源占用的场景。

局限性

  • 研究为回顾性设计,来自三个中心的数据可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To develop and validate a breast imaging reporting and data system (BI-RADS) based on conventional ultrasonography (US) and contrast-enhanced US (CEUS) to stratify the malignancy risk of breast lesions and reduce unnecessary punctures.

MATERIALS AND METHODS: This retrospective multicenter study evaluated 1465 patients with 1624 breast lesions who underwent conventional US, CEUS and received a final diagnosis from three centers. Patients from Center 1 were randomized into a training set (70%) and internal validation set (30%). Patients from Center 2 and Center 3 formed external validation sets. Qualitative US features of the breast lesions were analyzed with univariable and multivariable logistic regression. By rounding the regression coefficients of the multivariable logistic analysis to obtain scores, we developed the CEUS BI-RADS. The performance of CEUS BI-RADS in terms of discrimination, calibration and clinical utility was evaluated by receiver operating characteristic curves, calibration curves and decision curve analysis, respectively.

RESULTS: In the internal validation set, the area under the receiver operating characteristic curve value of CEUS BI-RADS was significantly higher than that of conventional US BI-RADS (0.95 [95% confidence interval (CI): 0.92, 0.97] vs. 0.80 [95% CI: 0.76, 0.85], p < 0.001). Moreover, CEUS BI-RADS yielded a considerably better sensitivity (90% [122/135] vs. 76% [103/135]), specificity (80% [205/255] vs. 73% [187/255]), positive predictive value (71% [122/172] vs. 60% [103/171]) and negative predictive value (94% [205/218] vs. 85% [187/219]) than that of conventional US BI-RADS (p < 0.05 for all). Significantly also, the unnecessary biopsy rate declined from 40% (68/171) to 29% (50/172) (p = 0.037).

CONCLUSION: A new, practical BI-RADS based on the features of conventional US and CEUS was developed, which had better diagnostic value than existing BI-RADS.

CLINICAL RELEVANCE STATEMENT: The CEUS BI-RADS, which combined the features of conventional US and CEUS, significantly reduced the rate of unnecessary biopsy of breast lesions while maintaining relatively high sensitivity and specificity, showing its potential in alleviating patients' anxiety, reducing the burden on medical resources and improving diagnostic efficiency.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Qiu, Zhang, Liu, et al. A New Contrast-Enhanced Ultrasound (CEUS) Reporting and Data System for Breast Lesions. Ultrasound Med Biol. 2026. PMID: 42791173. doi:10.1016/j.ultrasmedbio.2026.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。